At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
BMN 111 +1 moredrug
Likely dose
BMN 111 15 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months
In Brief
A Phase 2 clinical trial evaluating BMN 111 and Placebo for Achondroplasia. Completed, enrolled 75 participants across 16 sites in 4 countries.
Detailed Summary
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAchondroplasia
CountriesAustralia, Japan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionJan 2022
TodayJul 2026
First PostedJul 11, 2018
Enrollment StartJun 13, 2018
Primary CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.0 years ago
Interventions
BMN 111drug
Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
Placebodrug
Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol